When a peptide is synthesized, purified, and packaged, one of the less visible but more consequential quality checks involves looking for contamination that has nothing to do with the peptide itself. Bacterial endotoxins — fragments shed by certain bacteria during their normal life cycle and death — are invisible, heat-stable, and capable of triggering severe physiological responses even at very low concentrations. Understanding what they are and how labs test for them is a core part of evaluating any injectable compound's safety profile.
What Bacterial Endotoxins Are
Endotoxins are lipopolysaccharides (LPS) — complex molecules found in the outer membrane of gram-negative bacteria such as *E. coli* and *Salmonella*. When these bacteria die or replicate, fragments of their cell wall — including LPS — are released into the surrounding environment. Unlike many biological contaminants, endotoxins are not living organisms and cannot be killed. Standard sterilization methods such as autoclaving destroy bacteria but leave endotoxin fragments intact and biologically active.
Once introduced into the bloodstream, endotoxins interact with the immune system's toll-like receptor 4 (TLR4) pathway — a mechanism well-described in immunology literature. Research reports that even small amounts can trigger a cascade of inflammatory signaling, leading to fever, chills, and in severe cases, a systemic inflammatory response sometimes called endotoxemia or, at its most extreme, septic shock. For oral or topical products, endotoxin exposure through intact membranes is far less consequential. For injectables, the risk profile is fundamentally different.
Why Injectables Require Endotoxin Testing
Pharmaceutical regulators — including the FDA, EMA, and USP — require endotoxin limits for injectable drugs as a standard part of release testing. The USP chapter <85> (Bacterial Endotoxins Test) and its international equivalents define the accepted methods and limits. The threshold commonly cited for most injectable drugs is 5 EU/kg/hour (endotoxin units per kilogram of body weight per hour), though the specific limit varies by product type and route of administration; always defer to official pharmacopoeial references for precise figures.
Research-use peptides — compounds synthesized for laboratory or investigational purposes and not approved for human use — are not formally subject to the same regulatory release testing as licensed pharmaceuticals. However, third-party labs that specialize in peptide quality assessment increasingly offer endotoxin testing as a reported data point, allowing researchers to assess contamination levels in the same framework regulators use.
How Labs Measure and Report Endotoxins
The dominant testing method is the Limulus Amebocyte Lysate (LAL) test, which uses a clotting agent derived from horseshoe crab blood (*Limulus polyphemus*). LAL reagent is exquisitely sensitive to LPS; in the presence of endotoxin, it triggers a detectable clotting or color-change reaction. A more recent alternative — the recombinant Factor C (rFC) assay — achieves similar sensitivity without requiring horseshoe crab-derived material and is increasingly accepted in regulatory contexts.
Results are reported in EU/mL (endotoxin units per milliliter of solution). An EU is a standardized unit calibrated against a reference endotoxin preparation maintained by the FDA and WHO. Labs such as Janoshik and others in the third-party peptide-testing space typically report a numeric EU/mL value alongside the method used and the detection limit of the assay. A result below the assay's detection threshold is reported as "less than X EU/mL" rather than zero, reflecting the inherent limit of measurement.
| Term | What it means |
|---|---|
| EU/mL | Endotoxin units per milliliter of solution tested |
| LAL test | Limulus Amebocyte Lysate — standard method using horseshoe crab lysate |
| rFC assay | Recombinant Factor C — animal-free alternative to LAL |
| Detection limit | Lowest concentration the assay can reliably detect; results below are reported as "<X EU/mL" |
| USP <85> | US Pharmacopeia chapter defining bacterial endotoxin test methods and acceptance criteria |
When reviewing a third-party certificate of analysis (COA), the endotoxin result should specify the method, the reported value or detection limit, and ideally the sample preparation method — since dilution factors and matrix effects can influence results. A COA that lists only a pass/fail without a numeric value or method provides less verifiable information than one with full detail.
Sources
- USP Bacterial Endotoxins Test (USP <85>) — usp.org
- FDA Guidance on Endotoxin Testing — fda.gov
- EMA Guidelines on Endotoxins for Parenteral Products — ema.europa.eu
- PubMed: LPS and TLR4 signaling literature — pubmed.ncbi.nlm.nih.gov
- Janoshik Analytical Testing (third-party COA provider) — janoshik.com
- Finnrick Peptide Lab Test Aggregator — finnrick.com